Parkinsonian symptoms arise due to over-activity of the indirect striatal output pathway, and under-activity of the direct striatal output pathway. L-DOPA-induced dyskinesia (LID) is caused when the opposite circuitry problems are established, with the indirect pathway becoming underactive, and the direct pathway becoming overactive. Here, we define synaptic plasticity abnormalities in these pathways associated with parkinsonism, symptomatic benefits of L-DOPA, and LID. We applied spike-timing dependent plasticity protocols to cortico-striatal synapses in slices from 6-OHDA-lesioned mouse models of parkinsonism and LID, generated in BAC transgenic mice with eGFP targeting the direct or indirect output pathways, with and without L-DOPA present. In naïve mice, bidirectional synaptic plasticity, i.e. LTP and LTD, was induced, resulting in an EPSP amplitude change of approximately 50% in each direction in both striatal output pathways, as shown previously. In parkinsonism and dyskinesia, both pathways exhibited unidirectional plasticity, irrespective of stimulation paradigm. In parkinsonian animals, the indirect pathway only exhibited LTP (LTP protocol: 143.5 ± 14.6%; LTD protocol 177.7 ± 22.3% of baseline), whereas the direct pathway only showed LTD (LTP protocol: 74.3 ± 4.0% and LTD protocol: 63.3 ± 8.7%). A symptomatic dose of L-DOPA restored bidirectional plasticity on both pathways to levels comparable to naïve animals (Indirect pathway: LTP protocol: 124.4 ± 22.0% and LTD protocol: 52.1 ± 18.5% of baseline. Direct pathway: LTP protocol: 140.7 ± 7.3% and LTD protocol: 58.4 ± 6.0% of baseline). In dyskinesia, in the presence of L-DOPA, the indirect pathway exhibited only LTD (LTP protocol: 68.9 ± 21.3% and LTD protocol 52.0 ± 14.2% of baseline), whereas in the direct pathway, only LTP could be induced (LTP protocol: 156.6 ± 13.2% and LTD protocol 166.7 ± 15.8% of baseline). We conclude that normal motor control requires bidirectional plasticity of both striatal outputs, which underlies the symptomatic benefits of L-DOPA. Switching from bidirectional to unidirectional plasticity drives global changes in striatal pathway excitability, and underpins parkinsonism and dyskinesia.
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Parkinsonism and dyskinesia are caused by basal ganglia circuitry abnormalities originating in the striatum (Albin et al., 1989 (Albin et al., , 1995 Crossman, 1989 Crossman, , 1990 DeLong, 1990) . Output neurons comprise 95% of the striatal neuronal population, with two distinct trajectories. The direct pathway is monosynaptic and terminates in the globus pallidus interna (GPi) and substantia nigra pars reticulata (SNr). The indirect pathway synapses in the globus pallidus externa (GPe) and subthalamic nucleus (STN) before terminating in the SNr and GPi. Each pathway expresses distinct receptor subtypes, impacting motor control differently. Within the striatum, the direct pathway expresses dopamine D1 receptors, whereas the striatal neurons associated with the indirect pathway express dopamine D2 and adenosine A2a receptors (Albin et al., 1989; Gerfen et al., 1990; Kravitz et al., 2010) . Parkinsonism involves over-activity and under- 
